Related Experiment Video

Updated: Jul 9, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

Hypothyroidism among pediatric cancer patients: a nationwide, registry-based study

Laura-Maria S Madanat1, Päivi M Lähteenmäki, Saija Hurme

  • 1Department of Pediatrics, Turku University Hospital, Turku, Finland.

International Journal of Cancer
|December 14, 2007
PubMed

Insights

Childhood cancer survivors have a significantly higher risk of developing hypothyroidism (HT) compared to the general population. Early diagnosis and tailored thyroid function follow-up are crucial for these survivors.

Area of Science:

  • Endocrinology
  • Pediatric Oncology
  • Public Health

Background:

  • Childhood cancer survivors face long-term health risks, including endocrine disorders.
  • Hypothyroidism (HT) is a potential late effect of cancer treatment.
  • Effective monitoring strategies for HT in this population are essential.

Purpose of the Study:

  • To determine the incidence and prevalence of hypothyroidism (HT) in childhood cancer survivors.
  • To identify risk factors and specific cancer types associated with higher HT risk.
  • To inform the planning of thyroid function follow-up protocols.

Main Methods:

  • Utilized Finnish Cancer Registry data for 5,180 childhood cancer patients (diagnosed aged 0-15, born after 1970).
  • Linked cancer data with thyroxin reimbursement and prescription databases from the Social Insurance Institution.
  • Analyzed data to calculate HT prevalence and incidence rates and assess risk factors.

Main Results:

  • HT prevalence in survivors under 35 was 10,509/100,000, significantly higher than the general population (240/100,000).
  • Cancer diagnostic group and gender significantly impacted HT risk; males were less prone.
  • Highest cumulative incidence of HT was observed in survivors of thyroid cancer, Hodgkin lymphoma, CNS tumors, and neuroblastoma.

Conclusions:

  • Childhood cancer survivors exhibit a substantially elevated risk of developing hypothyroidism.
  • Specific cancer types and patient gender are significant predictors of HT development.
  • Findings support the need for tailored, diagnostic group-specific thyroid function surveillance in childhood cancer survivors.

Related Concept Videos

Hypothyroidism II: Pathophysiology01:23

Hypothyroidism II: Pathophysiology

Hypothyroidism is a disorder characterized by insufficient production of thyroid hormones, which regulate metabolism, energy balance, and multiple organ systems.TypesHypothyroidism is classified based on the level of dysfunction. Primary hypothyroidism results from intrinsic thyroid gland dysfunction, causing reduced hormone production despite normal or increased stimulation. Secondary hypothyroidism arises from inadequate thyroid-stimulating hormone (TSH) secretion by the pituitary. Tertiary...
Hyperthyroidism II: Pathophysiology01:27

Hyperthyroidism II: Pathophysiology

Hyperthyroidism is a hypermetabolic state caused by elevated levels of thyroid hormones, triiodothyronine (T3) and thyroxine (T4). It results from dysregulation at the thyroid, pituitary, or immune system level and affects multiple organ systems.PathophysiologyThe most common cause of hyperthyroidism is Graves’ disease, an autoimmune disorder in which antibodies, specifically thyroid-stimulating antibodies (TSAb), a subtype of TSH receptor antibodies (TRAb), bind to and activate TSH receptors...
Hyperthyroidism I: Introduction01:25

Hyperthyroidism I: Introduction

Hyperthyroidism is a type of thyrotoxicosis characterized by the thyroid gland's overproduction of the thyroid hormones triiodothyronine (T3) and thyroxine (T4). This hormone excess increases the basal metabolic rate and enhances sensitivity to catecholamines.DiagnosisDiagnosis is based on clinical features and biochemical testing. It typically shows suppressed thyroid-stimulating hormone (TSH) levels below 0.4 mIU/L, with elevated free T3 and/or T4. Additional tests, including thyroid...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...